Chemical Structure : Sutimlimab
CAS No.: 2049079-64-1
货号: PC-Ab1041Not For Human Use, Lab Use Only.
Sutimlimab (BIVV009, TNT-009) is a humanized mAb that specifically inhibits the complement (CP)-specific serine protease C1s to evaluate the impact of upstream CP antagonism on activation and proliferation of normal and autoimmune human B cells. Sutimlimab potentially reduce RBC lysis, significantly inhibited complement-mediated activation and proliferation of primary human B cells. antagonism suppressed human Ig-induced activation of B cells derived from patients with rheumatoid arthritis..
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥3580 | In stock | |
5 mg | ¥7580 | In stock | |
10 mg | ¥12800 | In stock | |
100 mg | Get quote |
大包装,大折扣!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Sutimlimab (BIVV009, TNT-009) is a humanized mAb that specifically inhibits the complement (CP)-specific serine protease C1s to evaluate the impact of upstream CP antagonism on activation and proliferation of normal and autoimmune human B cells. Sutimlimab potentially reduce RBC lysis, significantly inhibited complement-mediated activation and proliferation of primary human B cells. antagonism suppressed human Ig-induced activation of B cells derived from patients with rheumatoid arthritis.
分子量 | ||
分子式 | Human IgG4-Kappa | |
外观性状 | Solid | |
储存条件 |
|
|
Solubility |
PBS, pH 7.0 Contains no stabilizers or preservatives |
|
Chemical Name/SMILES |
Sutimlimab; BIVV009; BIVV 009; TNT-009; TNT009; 2049079-64-1; C1 complement complex; complement subcomponent C1 |
1. 1, Jäger U, et al. Blood. 2019 Feb 28;133(9):893-901. 2, Barcellini W, et al. J Clin Med. 2020 Nov 27;9(12):3859. 3, Röth A, et al. N Engl J Med. 2021 Apr 8;384(14):1323-1334. 4, Nikitin PA, et al. J Immunol. 2019 Feb 15;202(4):1200-1209. 5, Gelbenegger G, et al. Blood Adv. 2020 Mar 24;4(6):997-1005.
备案号:沪ICP备16042516号-1 Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright